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A role for reproductive and hormonal factors on colorectal carcino-
genesis has long been suggested, since an excess of colorectal
cancer was reported in nuns (Fraumeni et al, 1969); also, several
studies have found an inverse relation between hormone replace-
ment therapy (HRT) and colorectal cancer risk (Herbert-Croteau,
1998). Over the last two decades colorectal cancer mortality has
declined more in women than in men in several developed coun-
tries (La Vecchia et al, 1998). This may be due to earlier or greater
dietary improvements than in men, but exogenous hormones may
also play a role (Fernandez et al, 2000a). 
Several studies have also provided information on use of
combined oral contraceptives (OC) and the risk of colorectal
cancer including four cohort studies (IARC Monographs, 1999),
of which three showed relative risks (RR) for ever OC use below
unity (statistically significant in one). There have been 11 case-
control studies, none of which showed significantly elevated risks.
The RRs were below unity for 9 studies, and significant in two
(IARC Monographs, 1999). 
It is therefore of interest to combine all published data on OC
and colorectal cancer, to obtain overall and quantitative estimates
of the potential association for ever versus never use, and
according to duration and recency of use. 
METHODS 
Articles considered were epidemiological studies on colorectal
cancer published as full papers in English up to June 2000 that
included quantitative information on OC use. They were identified
by reviewing reference lists in relevant papers, manual and
computerized search in Medline and Cancerlit databases, and
discussions with colleagues to update the papers included in the
IARC Monograph (IARC Monographs, 1999) and a previous
review (Franceschi and La Vecchia, 1998). Search strategy
included a range of synonyms of neoplasms, tumours, or cancer of
colon and/or rectum and of exogenous female hormones, oral
contraceptives, oestro-progestins, etc. Studies were eligible only if
information had been obtained from each woman, and OCs were
distinguishable from hormone replacement and other hormonal
therapies. For this reason, we did not include a record-linkage
cohort study (Risch and Howe, 1995), which reported no associa-
tion of OC use with colorectal cancer, and a case-control study
(Gerhardsson de Verdier and London, 1992), which showed an
inverse association with the use of any female hormone. 
A total of 20 papers was reviewed, including 6 from cohort
(Chute et al, 1991; Bostick et al, 1994; Martinez et al, 1997; Troisi
et al, 1997; Beral et al, 1999; van Wayenburg et al, 2000), and 14
from case-control investigations (Weiss et al, 1981; Potter and
McMichael, 1983; Furner et al, 1989; Negri et al, 1989; Kune et al,
1990; Peters et al, 1990; Franceschi et al, 1991; Wu-Williams et al,
1991; Jacobs et al, 1994; Kampman et al, 1994; Fernandez 
et al, 1996; Kampman et al, 1997; Fernandez et al, 1998; Talamini
et al, 1998). Among the cohort studies, only the more recent of the
two papers from the Nurses’ Health Study (Chute et al, 1991;
Martinez et al, 1997) were considered. Among case-control studies,
one article (Wu-Williams et al, 1991) included two nonoverlapping
study populations from two different geographical areas, and both
were included in the meta-analysis. There were 5 articles from 3
case-control studies conducted in Italy: 3 of them (Negri et al,
1989; Franceschi et al, 1991; Fernandez et al, 1996) from two
companion studies conducted between 1985 and 1992 in Northern
Italy, another (Talamini et al, 1998) from a third study conducted
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between 1992 and 1996 in 6 Italian areas, and a pooled analysis
(Fernandez et al, 1998) that included all studies; the most recent
results were routinely included. 
For each study, details were extracted on study design, number
of subjects (cases and controls or person-years), prevalence of OC
use, and control of confounding. Primary analysis concerned the
comparison of ever versus never users of OCs, but the influence of
duration and recency of use was assessed, wherever possible. In
most studies, the combination of cancers of the colon and rectum
was, in most instances, the primary outcome, but some concerned
only colon cancer, while a few considered colon and rectum
separately. We did not assign any quality score to each study, and
no studies were excluded a priori for weaknesses of design or data
quality. 
The measure of effect of interest is the RR for cohort studies,
approximated by the odds ratio in case-control studies, and the
corresponding statistical significance (95% confidence interval,
CI). Summary estimates of the RR were derived using fixed
effects models, and heterogeneity was evaluated using a c2 test for
heterogeneity (Greenland, 1987) and the Galbraith plot (Galbraith,
1988). 
Publication bias was evaluated using funnel plots (Thornton and
Lee, 2000) and Egger’s test (Egger et al, 1997). The RRs and CIs
were abstracted from published papers by two of the authors (AB,
EF), giving preference to estimates adjusted for multiple
confounding factors. When multivariate RRs were not available,
these were computed from exposure distribution as given in the
articles. There was however little difference between these and the
multivariate-adjusted RRs. The weighted average of the estimated
RRs was computed by giving each study a weight proportional to
its precision (i.e., the inverse of the variance, estimated, when
necessary, by calculating the standard errors from the CIs).
Summary estimates were calculated for the two types of study
separately, as well as in combination. 
A graph was given in which a square was plotted for every
study, whose centre projection on the underlying scale cor-
responded to the estimated RR. The area of the square was propor-
tional to the inverse of the variance of the natural logarithm of the
RR (Collaborative Group on Hormonal Factors in Breast Cancer,
1996). 
RESULTS 
Details of the studies included in the meta-analysis are shown in
Table 1 (cohort) and Table 2 (case-control studies). 
Figure 1 gives the RRs for ever versus never OC users in the eight
case-control and the four cohort studies providing data. The pooled
RR from the case-control studies was 0.81 (95% CI: 0.69–0.94).
There was significant heterogeneity among the case-control studies
(c2 = 26.26, 7 d.f.; P = 0.0005). This, however, was largely due to
the study by Weiss et al (1981), which included in the reference
group both never users of OCs and users of <1 year. After excluding
this study, the summary RR was 0.72 (95% CI: 0.61–0.85), and the
heterogeneity was reduced (c2 = 12.59, 6 d.f.; P = 0.05). The pooled
estimate from cohort studies was 0.84 (95% CI: 0.72–0.97), in the
absence of significant heterogeneity (c2= 4.18, 3 d.f.; P= 0.24). The
pooled estimate from all studies combined was 0.82 (95% CI:
0.74–0.92). No heterogeneity was present between case-control and
cohort studies. No material differences were observed between
summary estimates computed from exposure distribution and those
derived from multivariate estimates, and hence the fully adjusted
estimates were used, whenever available. 
For colon cancer (2 cohort and 9 case-control studies, Figure 2),
the summary RR was 0.83 (95% CI: 0.74–0.95), without hetero-
geneity between studies (P = 0.21). For rectal cancer (1 cohort and
5 case-control studies, Figure 3), the summary RR was 0.74 (95%
CI: 0.59–0.93), and the heterogeneity between studies was of
borderline statistical significance (P = 0.05). 
Table 3 gives the summary risk estimates according to different
measures of OC use. Duration of use was not related to decrease in
risk, since the overall RR of colorectal cancer was 0.78 for short
duration of use and 0.85 for long duration. Similarly, no consistent
pattern was evident for colon and rectal cancers. Only 2 studies
(Fernandez et al, 1998; Beral et al, 1999) included information on
recency of use, and there was some indication that the apparent
protection was stronger for women who had used OCs more
recently (RR = 0.46; 95% CI: 0.30–0.71). 
Table 1 Cohort studies on oral contraceptives and colorectal cancer 
Reference Country Population (follow-up) No. of cancers 
Chute et al, 1991; Martinez et al, 1997 US Nurses’ Health Study 89 448 (12 years) 501 
Bostick et al, 1994 Iowa, US 35 215 (4 years) 212 
Troisi et al, 1997 US BCDDP 57 528 (10 years) 95 
Beral et al, 1999 UK RCGP OC Study 46 000 (25 years) 170 deaths 
van Wayenburg et al, 2000 Netherlands 10 671 (18 years) 95 deaths 
RCGP = Royal College of General Practitioners; BCDDP = Breast Cancer Detection Demonstration Project. 
Table 2 Case-control studies on oral contraceptives and colorectal 
cancer 
Reference Country Cases:Controls 
Weiss et al, 1981 Washington, State, US 143:707 
Potter and McMichael, 1983 Adelaide, Australia 155:311 
Furner et al, 1989 Chicago, US 90:208 
Kune et al, 1990 Melbourne, Australia 190:200 
Negri et al, 1989
Franceschi et al, 1991
Fernandez et al, 1996
Talamini et al, 1998
Fernandez et al, 1998 Italy 1232:2793 
Peters et al, 1990 Los Angeles, US 327:327 
Wu-Williams et al, 1991 N. America and China 395:1112 
Jacobs et al, 1994 Seattle, US 193:194 
Kampman et al, 1994 The Netherlands 102:123 
Kampman et al, 1997 US, KPMC 894:1120 
KPMC = Kaiser Permanente Medical Care. 724 E Fernandez et al 
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DISCUSSION 
This meta-analysis of published studies found a 18% reduction in
colorectal cancer risk among ever OC users. This effect was appar-
ently stronger for recent OC use, but there was no duration 
effect. There was more heterogeneity in case-control than in cohort
studies but this was mainly due to one study (Weiss et al, 1981),
which was concluded in the years 1976–1977 and did not include a
category for never OC users. Apart from one other (Kune et al,
1990), this was the only study to show an increased risk among ever
users, and both suffered from low participation rates among cases
(about 61%). Since the observed heterogeneity in the meta-analysis
Table 3 Oral contraceptives and colorectal cancer: summary RR+ estimates according to duration and recency of use 
RR+ 95% CI+ Studies 
Duration of use (based on reported multivariate RR)
Colorectal cancer 
<5 years 0.78 0.64–0.95 Troisi et al, 1997; Beral et al, 1999; Weiss et al, 1981; Fernandez et al, 
1998 
³5 years 0.85 0.63–1.14
Colon cancer
<5 years 0.81 0.65–1.02 Chute et al, 1991; Fernandez et al, 1998; Peters et al, 1990; Jacobs et al, 
1994 
³5 years 0.79 0.60–1.05
Rectal cancer
<5 years 1.05 0.68–1.64 Chute et al, 1991; Fernandez et al, 1998 
³5 years 0.94 0.59–1.50
Recency of use (based on reported multivariate RR)
Colorectal
<10 years 0.46 0.30–0.71 Beral et al, 1999; Fernandez et al, 1998 
³10 years 0.77 0.67–0.89
+RR indicates relative risk; CI confidence interval.
0.0 0.5 1.0 1.5
OR ± SD
1.68 ± 0.36
1.63 ± 0.17
0.64 ± 0.23
1.36 ± 0.33
1.84 ± 0.20
0.74 ± 0.11
0.84 ± 0.08
1.00 ± 0.15
0.60 ± 0.12
0.68 ± 0.06
OR & 95% CI
Test for heterogeneity between subtotals: c2 (1 d.f.) = 0.11; P = 0.74
Test for heterogeneity between subtotals: c
2 (11 d.f.) = 30.55; P = 0.00
Test for heterogeneity between subtotals: c2 (3 d.f.) = 4.18; P = 0.24
+ Relative to never users of oral contraceptives
* Data not given
Test for heterogeneity between subtotals: c
2 (7 d.f.) = 26.26; P = 0.00
Cohort studies
1999 Beral 29/* 39/* – 0.51 0.21
1981 Weiss 47/164 96/543 – 0.52 0.21
1989 Kune 47/39 143/161 – 0.30 0.24
1996 Fernandez 30/92 679/900 – 0.76 0.19
1989 Furner 9/32 80/175 – 0.45 0.37
1983 Potter 18/55 137/256 – 0.46 0.27
*/* 95/* – 0.39 0.60
Subtotal: 252/* 742/* – 0.18 0.08
Total:
251/760 1937/4317 – 0.21 0.08 Subtotal:
Case – control studies
STUDY Case/Controls Case/Controls b SD (b)
EVER NEVER STATISTICS ODDS RATIO +
2.0
503/760 2679/4317 – 0.19 0.05
2000 Van Wayenburg
1991 Wu – Williams/CHN 18/74 188/544 – 0.33 0.26
1991 Wu – Williams/NA 26/79 163/415 – 0.17 0.24
1.72 ± 0.18
0.47 ± 0.09
0.81 ± 0.06
0.82 ± 0.04
P= 0.0004
1998 Talamini 56/225 451/1323 – 0.30 0.15
1998 Troisi 57/* 273/* – 0.00 0.15
1996 Martinez 166/* 335/* – 0.17 0.10
Figure 1 Summary of relative risk estimates of colorectal cancer for ever vs. never use of oral contraceptives from case-control and cohort studies Oral contraceptives and colorectal cancer 725
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was attributable to two of the studies included, we chose to use the
fixed effect model rather than the random effect model, which is
preferable when the heterogeneity has no simple explanation
(Greenland, 1987). 
With reference to publication bias, we decided a priori not to
search for unpublished data or abstracts, and to exclude studies not
based on personal questionnaires. Studies with null results or small
sample sizes are less likely to be published (Dickersin and Min,
Figure 2 Summary of relative risk estimates of colon cancer for ever vs. never use of oral contraceptives 
Figure 3 Summary of relative risk estimates of rectal cancer for ever vs. never use of oral contraceptives 
0.0 0.5 1.0 1.5
OR ± SD
0.50 ± 0.13
1.17 ± 0.41
1.02 ± 0.28
0.55 ± 0.21
1.16 ± 0.30
0.86 ± 0.11
0.83 ± 0.06
0.80 ± 0.12
0.96 ± 0.18
0.86 ± 0.10
OR & 95% CI
Test for heterogeneity between subtotals: c
2 (1 d.f.) = 0.08; P = 0.77
Test for heterogeneity between subtotals: c
2 (10 d.f.) = 13.32; P = 0.21
Test for heterogeneity between subtotals: c2 (1 d.f.) = 0.60; P = 0.44
+ Relative to never users of oral contraceptives
* Data not given
Test for heterogeneity between subtotals: c
2 (8 d.f.) = 12.63; P = 0.13
Cohort studies
1991 Chute 60/* 131/* – 0.22 0.15
1983 Potter 10/55 89/256 – 0.69 0.26
1991 Wu – Williams/CHN 5/74 73/544 – 0.60 0.38
1994 Kampman 46/58 50/63 – 0.03 0.38
1989 Peters 59/62 268/265 – 0.02 0.28
1989 Kune 24/39 84/161 – 0.16 0.35
37/* 175/* – 0.04 0.18
Subtotal: 97/* 306/* – 0.15 0.11
Total:
483/1022 2215/5144 – 0.19 0.08 Subtotal:
Case – control studies
STUDY Case/Controls Case/Controls b
SD (b)
EVER NEVER STATISTICS ODDS RATIO +
2.0
580/1022 2521/5144 – 0.18 0.06
1994 Bostick
1991 Wu – Williams/NA 21/79 93/415 – 0.18 0.28
1994 Jacobs 53/52 140/141 – 0.15 0.26
1.20 ± 0.34
0.97 ± 0.37
0.63 ± 0.11
0.84 ± 0.05
P= 0.0046
1996 Kampman 206/280 674/829 – 0.15 0.13
1998 Fernandez 59/323 744/2470 – 0.46 0.17
0.5 1.0 1.5 2.0
OR ± SD
0.70 ± 0.30
2.04 ± 0.74
0.70 ± 0.21
0.40 ± 0.14
0.66 ± 0.15
0.73 ± 0.10
0.76 ± 0.17
0.76 ± 0.17
0.74 ± 0.09
P = 0.0101
OR & 95% CI
Test for heterogeneity between subtotals: c
2 (1 d.f.) = 0.02; P = 0.88
Test for heterogeneity between subtotals: c2 (5 d.f.) = 11.23; P = 0.05
Test for heterogeneity between subtotals: c
2 (0 d.f.) = 0.00; P = 
+ Relative to never users of oral contraceptives
* Data not given
Test for heterogeneity between subtotals: c2 (4 d.f.) = 11.20; P = 0.02
Cohort studies
1997 Martinex */* */* – 0.27 0.22
1983 Potter 8/55 48/256 – 0.36 0.43
1991 Wu – Williams/NA 5/79 70/415 – 0.92 0.35
1998 Fernandez 30/323 399/2470 – 0.42 0.22
1991 Wu – Williams/CHN 13/74 115/544 – 0.36 0.30
1989 Kune 23/39 59/161 – 0.71 0.36
*/* */* – 0.27 0.22 Subtotal:
79/570 691/3846 – 0.30 0.12 Total:
79/570 691/3846 – 0.31 0.14 Subtotal:
Case – control studies
STUDY Case/Controls Case/Controls b SD (b)
EVER NEVER STATISTICS ODDS RATIO +726 E Fernandez et al 
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1993). In the present meta-analyses, however no significant asym-
metry was present in the funnel plots, and this can be considered
an indicator of the validity of the results. 
An important problem concerns allowance for potential
confounding factors, including diet, physical activity, socio-
economic indicators and other correlates of colorectal cancer
(Potter et al, 1993, 1999). However, the fact that the use of multi-
variate RRs gave similar pooled estimates to unadjusted ones indic-
ates that the confounding or modifying effect of major considered
covariates is unlikely to be substantial. 
Most data were collected in the 1980s and 1990s from women
with a mean age of 55 to 60 years, and therefore largely refer to
OC use between the mid 1960s and the mid 1980s. No information
was available on type of OC, but no heterogeneity or systematic
trend by calendar year was observed. 
Female hormones may protect against colorectal cancer as a
result of changes in bile synthesis and secretion, which lead to
reduced concentration of bile acids in the colon (McMichael and
Potter, 1985). Other biological mechanisms may however be
involved, and none of them appears clearly established. Oestrogens
inhibit the growth of colon cancer cells in vitro (Lointier et al,
1992), and oestrogen receptors have been identified in normal and
neoplastic colon epithelial cells (Thomas et al, 1993). The
oestrogen receptor (ER) gene might play a tumour suppressor role,
since the hypermethylation of the promotor region of the ER gene
results in a reduced expression and deregulated growth in colonic
mucosa (Issa et al, 1994). Oestrogens may reduce serum insulin-
like growth factor-l (IGF-1) (Campagnoli et al, 1998), a mitogen
that has been linked to an increased risk of colorectal cancer (el
Atiq et al, 1994; Giovannucci et al, 2000). 
Available data therefore suggest that OC use is inversely related
to the risk of colorectal cancer. These results are in broad agree-
ment with the descriptive epidemiology of colorectal cancer (dos
Santos Silva and Swerdlow, 1996; Fernandez et al, 2000a), with
the observation of an inverse relation between HRT and colorectal
cancer risk (Herbert-Croteau, 1998; Fernandez et al, 2000b), and
with biological hypotheses and experimental findings on the 
physiologic and molecular pathways of colorectal cancer (Mc-
Michael and Potter, 1985; Potter, 1999). A better understanding of
this potential relation may help informed choice of contraception
(La Vecchia et al, 1996). Some aspects, however, remain unde-
fined, including the risk profile with duration and recency of use,
and the possibility of confounding. The issue of causal inference
for the observed association is therefore still open to discussion. 
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